2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2594

Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials
Abstract Number: 2595

Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Abstract Number: 2596

Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade®) in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study
Abstract Number: 2597

Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry
Abstract Number: 2598

Conversion Rate of Tuberculosis Screening Tests in Patients with Rheumatic Diseases While Receiving Anti-Tumor Necrosis Factor Alpha (anti-TNFα) Agents
Abstract Number: 2599

TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation
Abstract Number: 2600

Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Abstract Number: 2601

A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Abstract Number: 2602

Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Abstract Number: 2603

Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Abstract Number: 2604

Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Abstract Number: 2605

Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Abstract Number: 2606

Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial
Abstract Number: 2607

Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy
Abstract Number: 2608

Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].